📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Journal Papers
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Eva Hajos-Korcsok, Jacob Hecksher-Sørensen, Urmas Roostalu, Steven P Vickers, Serena Wu, Christoph Anacker, Colleen Synan, Philip G Jones, Snezana Milanovic, Seth C…
Blog
How Does Automated Microscopy Expedite Imaging in Cell Biology?
In the vast realm of cell biology, innovative methods and pioneering technologies continuously redefine the…
Journal Papers
Key aspects of modern GPCR drug discovery
Phil Addis, Utsav Bali, Frank Baron, Adrian Campbell, Steven Harborne, Liz Jagger, Gavin Milne, Martin Pearce, Elizabeth M Rosethorne, Rupert Satchell, Denise Swift, Barbara Young, John F…
Journal Papers
Azetidines Kill Multidrug-Resistant Mycobacterium tuberculosis without Detectable Resistance by Blocking Mycolate Assembly
Yixin Cui, Alice Lanne, Xudan Peng, Edward Browne, Apoorva Bhatt, Nicholas J. Coltman, Philip Craven,…
Journal Papers
Structure–activity relationships for the G-quadruplex-targeting experimental drug QN-302 and two analogues probed with comparative transcriptome profiling and molecular modeling
Ahmed Abdullah Ahmed, Shuang Chen, Maria Roman-Escorza, Richard Angell, Sally Oxenford, Matthew McConville, Naomi Barton, Mihiro Sunose, Dan Neidle, Shozeb Haider, Tariq Arshad & Stephen Neidle  Abstract…
Blog
The Challenge of Childhood Cancers
Explore the distinctive challenges and promising advancements in paediatric oncology. Uncover innovative approaches shaping better outcomes for childhood cancers, reflecting our commitment to comprehensive and compassionate drug discovery.
Journal Papers
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
W Cameron Black, Abbas Abdoli, Xiuli An, Anick Auger, Patrick Beaulieu, Michel Bernatchez, Cathy Caron, Amandine Chefson, Sheldon Crane, Mohamed Diallo, Stéphane Dorich, Lee D Fader, Gino…
Journal Papers
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, Wendy Xolalpa, Allan Jordan, Roland Hjerpe, Manuel S. Rodriguez…
Blog
The resurgence of small molecule immuno-oncology therapies
Insights from Dr. Allan Jordan, Sygnature's VP of Oncology Drug Discovery into the reasons behind the struggles faced by inhibitors targeting IDO, TDO, and A2a receptors, and discover potential avenues for renewed hope, including agonists of the STING pathway and inhibitors of HPK-1 and Cbl-B.
News
Sygnature Discovery goes for global industry recognition with Chief Scientific Officer hire
Sygnature Discovery has announced a major new hire to its leadership team, with the…
Blog
The Energy Crisis in Brain Cells: The Pivotal Role of Mitochondrial Dysfunction in Neurodegeneration
Modulating mitochondrial function is an important…
News
Sygnature Discovery Receives EcoVadis Award For Sustainable Excellence
Latest update in 2025: Sygnature Discovery maintains its Bronze award for the second year running.
Blog
From Lab to Market: The Future of Mitochondrial Function in Neurodegeneration Therapy
Neurodegenerative disorders like Alzheimer’s Disease (AD), Huntington’s Disease (HD), Parkinson’s Disease (PD), and Amyotrophic…
Journal Papers
A decentralized solid compound storage facility managed by a centralized electronic platform at a growing drug discovery company
Ting Qin, Sergio Ernesto Ruiz Hernandez, Jason Shiers, Matthew Crittall, Andrew Novak, Colin Sambrook Smith Abstract Within a growing drug discovery company, scientists acquire (either through in house…
Blog
Psychedelics & Psychoplastogens – going more mainstream?
Psychedelic therapy gains traction, attracting big Pharma due to its potential beyond depression and PTSD. Regulatory shifts, including FDA guidelines, are sparking increased investor interest in this burgeoning field.
Webinars & Podcasts
The Pursuit of Mitochondrial Function for Large Pharma & Biotech
#MitochonriaUnlocked is a five-part video series from Dr. Tatiana Rosenstock, a neuroscientist at Sygnature Discovery. Across five short episodes, Tatiana shares real-world mitochondrial data and practical guidance to help decision-makers in the CNS disease space understand how, and why, mitochondrial health is becoming central to drug discovery.
Webinars & Podcasts
Benefits of Measuring Mitochondrial Function – Two Different Approaches
#MitochonriaUnlocked is a five-part video series from Dr. Tatiana Rosenstock, a neuroscientist at Sygnature Discovery. Across five short episodes, Tatiana shares real-world mitochondrial data and practical guidance to help decision-makers in the CNS disease space understand how, and why, mitochondrial health is becoming central to drug discovery.
Webinars & Podcasts
How Kinetics Experiments Unveil Organelle Complexity
#MitochonriaUnlocked is a five-part video series from Dr. Tatiana Rosenstock, a neuroscientist at Sygnature Discovery. Across five short episodes, Tatiana shares real-world mitochondrial data and practical guidance to help decision-makers in the CNS disease space understand how, and why, mitochondrial health is becoming central to drug discovery.
Webinars & Podcasts
Measuring Mitochondrial Dynamics and Biogenesis in Different Models
#MitochonriaUnlocked is a five-part video series from Dr. Tatiana Rosenstock, a neuroscientist at Sygnature Discovery. Across five short episodes, Tatiana shares real-world mitochondrial data and practical guidance to help decision-makers in the CNS disease space understand how, and why, mitochondrial health is becoming central to drug discovery.
Webinars & Podcasts
Conclusions on Mitochondria in Drug Development
#MitochonriaUnlocked is a five-part video series from Dr. Tatiana Rosenstock, a neuroscientist at Sygnature Discovery. Across five short episodes, Tatiana shares real-world mitochondrial data and practical guidance to help decision-makers in the CNS disease space understand how, and why, mitochondrial health is becoming central to drug discovery.
Blog
Intrinsically Disordered Proteins as Drug Discovery Targets
The intriguing world of the Intrinsically disordered proteins and why they are important as targets…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch